Nivolumab combination therapies improved overall survival in patients with advanced esophageal squamous cell carcinoma
1. Nivolumab in combination with chemotherapy or ipilimumab significantly prolonged overall survival compared to chemotherapy alone. 2. Common treatment-related adverse ...